{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"description":"The pharmacogenomics outcomes examining the correlation between the presence of the methylene tetrahydrofolate reductase gene and the presence of a polymorphism in the thymidylate synthase (TS) gene and/or gene promoter and toxicity were optional and will not be reported here. Results of this optional research may be reported in the future by the Children's Oncology Group in the peer-reviewed literature.","groups":[{"description":"Pemetrexed 1910 milligrams per meters squared (mg/m\\^2) (or 60 milligrams per kilogram \\[mg/kg\\] if patient \\<12 months old)","id":"OG000","title":"Osteosarcoma"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG001","title":"Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG002","title":"Rhabdomyosarcoma"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG003","title":"Neuroblastoma (Measureable Disease)"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG004","title":"Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG005","title":"Ependymoma"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG006","title":"Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor"},{"description":"Pemetrexed 1910 mg/m\\^2 (or 60 mg/kg if patient \\<12 months old)","id":"OG007","title":"Non-Brainstem High-Grade Glioma"}],"paramType":"NUMBER","populationDescription":"The pharmacogenomics outcomes examining the correlation between the presence of the methylene tetrahydrofolate reductase gene and the presence of a polymorphism in the thymidylate synthase (TS) gene and/or gene promoter and toxicity were optional and will not be reported here.","reportingStatus":"POSTED","timeFrame":"baseline","title":"Pharmacogenomics - Measure the Response of Genes Related to Toxicity","type":"SECONDARY","unitOfMeasure":"Correlation coefficient"}